SUNPHARMA.NS Dividend — how to research Sun Pharmaceutical's payout
Dividend research is about sustainability, not yield alone. This page shows the SUNPHARMA.NS dividend research workflow — what to check, where to find it, and how to know when the payout is at risk.
Balance Labs = AI Stock Chat · Berkshire fundamentals desk · Screener timing (US/HK/A-share/KR/India) · Free 30 AI credits/mo
Sun Pharmaceutical snapshot (2026-08-28)
| Snapshot | 2026-08-28 · source: yahoo-direct |
|---|---|
| Market | SUNPHARMA.NS |
| Sector | Pharma |
| Last price | ₹1,913 |
| Signal | LONG · uPnL +16.0% |
| Total return | +8.4% |
What to check before trusting a dividend
- Payout ratio — dividends ÷ earnings. Above 80% is a red flag for most sectors.
- Free cash flow coverage — the company needs actual cash, not accounting profit, to pay.
- Debt trajectory — rising debt + high payout = future cut risk.
- Dividend growth history — consistent raises signal confidence; freezes signal caution.
Calculator: free intrinsic value tool · workflow: Berkshire scorecard
Run the SUNPHARMA.NS dividend brief
Run the live brief — free
Stock Chat + Screener preview · 30 monthly AI credits · no card required. Covers US, HK, China A-share, Korea, India.
FAQ
Does Sun Pharmaceutical (SUNPHARMA.NS) pay a dividend?
Check the company's investor relations page for the latest dividend declaration. The Balance Labs SUNPHARMA.NS brief covers payout sustainability as part of the quality assessment — run it free for the current status.
What is SUNPHARMA.NS's dividend yield?
Dividend yield changes with price. The free SUNPHARMA.NS brief inside Balance Labs calculates yield based on the latest declared dividend and current price, with context on whether the payout is covered by earnings and free cash flow.
Is the SUNPHARMA.NS dividend safe?
Dividend safety depends on three checks: payout ratio (dividends ÷ earnings), free cash flow coverage, and debt levels. The Balance Labs workflow evaluates all three — run the free SUNPHARMA.NS brief for the scored assessment.
← All guides · Home · Not investment advice.